Details : URO-902 showed a clinically meaningful and statistically significant effect on a number of relevant outcome measures in OAB including number of micturitions, urgency episodes, and quality of life indicators compared to placebo, 12 weeks post-administrati...
Product Name : URO-902
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 03, 2022
Details : Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product URO-902 (hMaxi-K), showed clinically relevant improvement in the common symptoms of overactive bladder (OAB) compared to placebo.
Product Name : URO-902
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 13, 2022
Details : Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder and urge urinary incontinence will be featured in a late-breaker presentation during plenary session.
Product Name : URO-902
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 13, 2022
Urovant Sciences Announces Results from URO-902 Phase 1 Trials
Details : In the trials, URO-902 was well tolerated and the administration via direct injection procedure demonstrated statistically significant improvement in OAB symptoms.
Product Name : URO-902
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 02, 2020